Suisui Yang

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Suisui

Contact Suisui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Articles

Oncogene-induced senescence and senescence-associated secretory phenotype (SASP) determine the efficacy of palbociclib in PIK3CA mutated colorectal cancer

Nov 18, 2024 |

By Pingping Cao, Xiaohui Zhou, Tianqi Shen, Suisui Yang

| biorxiv.org

Abstract Palbociclib is an excellent CDK4/6 inhibitor, but its clinical application is mainly limited to the treatment of advanced ER+/HR+ and HER2- breast cancer. Its efficacy in colorectal cancer (CRC) is evaluated in multiple trials and so far remains undetermined.

Open in Who Shared

See all 1 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.

Claim your profile

Get in touch with Suisui

Contact Suisui, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

For PR Teams

Overview

Use Cases

Capabilities

Industries

Introducing Curation Engine

Resources

Library

Commmunity

Customers

Company

Suisui Yang

Get in touch with Suisui

Actions

Is this you?

Articles

Oncogene-induced senescence and senescence-associated secretory phenotype (SASP) determine the efficacy of palbociclib in PIK3CA mutated colorectal cancer

Actions

Is this you?

Get in touch with Suisui